Compugen Ltd.(CGEN)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Compugen's financial profile is defined by extreme volatility, where sporadic milestone payments create temporary profitability, such as the 84.4% net margin observed in 2025Q4.
• While the company maintains a conservative capital structure with a 0.03 debt-to-equity ratio, its long-term viability remains tethered to the success of its discovery platform and the timing of future pharmaceutical partnerships.
• Investors should remain cautious, as the business model historically relies on non-recurring inflows to offset persistent R&D expenditures that consistently range between $5.5M and $8.3M per quarter.